All stories tagged biotech on VentureGrill.
Warp Science is targeting the massive experimental bottleneck in biotechnology by pairing teleoperated robotics with physical laboratory workflows.
Former OpenAI executive Kevin Weil has raised a massive $215 million seed-stage round to leverage artificial intelligence in accelerating the drug development pipeline.
OpenAI has acquired Orchestra Bio, integrating the startup's team and technology into its Rosalind platform to advance AI models for life sciences research.
Max Hodak's Science Corporation has implanted its vision-restoring chip in a Stargardt disease patient, marking a critical clinical milestone for the Neuralink co-founder's new venture and setting a new benchmark for BCI investment. The move underscores the intense capital alloca
Trilantic North America realizes a $945 million exit with the sale of SOFIE Biosciences, capitalizing on surging strategic buyer appetite in the radiopharmaceuticals sector.
Evvy's $40 million Series B round, led by biotech investor Catalio Capital Management, signals a broader venture shift from consumer wellness apps to high-margin clinical diagnostics.
Electra Therapeutics raises $350 million in an upsized IPO, but a flat opening day underscores the cooling appetite for high-burn clinical-stage biotech assets.
Global venture funding into biotech startups has maintained a consistent trajectory, hovering between $36 billion and $40 billion annually, even as AI investment experiences dramatic shifts.
Vijay Pande, formerly leading a $4 billion biotech practice at a16z, has launched VZVC, a new AI-native fund focused on 'smaller bets,' signaling a strategic pivot in venture capital's approach to biotech innovation.
A classic $2 million seed round is no longer the default. New data shows early-stage venture capital is clustering into $5 million to $10 million 'mega-seeds' for deep tech, space, and biotech.
Miles Wang, an OpenAI researcher, is in talks to launch an AI-driven drug discovery startup valued at $2 billion, signaling strong investor appetite for AI applications in life sciences.